Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Cubist Pharmaceuticals to Acquire Optimer and Trius Therapeutics

By Pharmaceutical Processing | July 31, 2013

LEXINGTON, Mass. (AP) — Cubist Pharmaceuticals Inc. said Tuesday that it plans to acquire two other drug makers, Optimer and Trius Therapeutics, in an effort to expand its product portfolio.

The deals are valued at $801 million and $818 million, if certain milestones are reached, respectively.

Cubist, based in Lexington, Mass., develops antibiotics used for serious infections.

Its acquisition plans would give Cubist access to a drug, developed by Optimer and recently approved by the FDA, to treat Clostridium difficile-associated diarrhea in adults. This bacterium, often contracted while getting medical care, can cause problems ranging from diarrhea to life-threatening inflammation of the colon.

Dificid is the first antibacterial drug approved in more than 25 years to treat this type of diarrhea. The company said more than 700,000 cases occur annually in the U.S. and the disease is estimated to be responsible for approximately 14,000 deaths per year in the U.S.

Cubist plans to acquire all the outstanding shares of Optimer for $10.75 per share, or approximately $535 million. That represents a discount to the company’s closing price of $13.29 on Tuesday before the plans were made public.

However, each stockholder will also receive a contingent value right that entitles them to an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of Dificid are achieved. The contingent value right is expected to be publicly traded.

The boards of both companies have approved the deal, but it still needs shareholder approval.

Cubist said the acquisition was a perfect fit, given the company’s focus on acute care and hospital environments. The company also said there is a significant and rising need for the drug as these types of infections have become increasingly common.

The deal is expected to close later this year and Cubist expects it will be accretive to its earnings in the first year after that.

Cubist also stands to benefit from its acquisition of Trius by gaining access to a number of antibiotics it has under development. Trius has a late-stage antibiotic it is working on that could potentially be used to treat several types of serious infections, such as those caused by MRSA. It also has several pre-clinical antibiotic programs under development.

The company plans to buy all of the outstanding shares of Trius for $13.50 per share in cash, or approximately $707 million. That is above the company’s closing price of $11.71 on Tuesday.

In addition to the upfront cash payment, each Trius stockholder will receive one contingent value right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved.

Cubist and Trius boards have approved the deal. The companies expect it will close later this year.

Stephen Brozak, president of WBB Securities, said the acquisitions represent a “stunning” move by Cubist and said that they underscore how important antibiotics will become for the future of global health care. He also said that what makes the deals even more stunning is that large pharmaceutical companies were absent from the discussions, another example of how they have “missed the boat again.”

Shares of Trius soared more than 17 percent in after-hours trading to $13.75 on the news. Optimer shares fell nearly 8 percent to $12.24. Cubist shares increased more than 6 percent to $60.50.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE